Australia markets closed

Kura Oncology, Inc. (KURA)

NasdaqGS - NasdaqGS Real-time price. Currency in USD
Add to watchlist
18.50+0.17 (+0.93%)
At close: 04:00PM EDT
18.50 0.00 (0.00%)
After hours: 04:02PM EDT
Full screen
Trade prices are not sourced from all markets
Previous close18.33
Bid18.50 x 4000
Ask18.51 x 1300
Day's range17.83 - 19.18
52-week range10.41 - 21.29
Avg. volume637,300
Market cap1.233B
Beta (5Y monthly)1.39
PE ratio (TTM)N/A
EPS (TTM)-1.99
Earnings date03 Aug 2022 - 08 Aug 2022
Forward dividend & yieldN/A (N/A)
Ex-dividend dateN/A
1y target est35.88
  • GlobeNewswire

    Viridian Therapeutics Appoints Carrie Melvin as Chief Operating Officer

    WALTHAM, Mass., June 23, 2022 (GLOBE NEWSWIRE) -- Viridian Therapeutics, Inc. (NASDAQ: VRDN), a biotechnology company advancing new treatments for patients suffering from serious diseases underserved by current therapies, today announced the appointment of Carrie Melvin as Chief Operating Officer, a newly created position at the company. “As we prepare for late-stage clinical development for our TED programs, we are excited to add Carrie to the Viridian team” said Jonathan Violin, Ph.D., Viridia

  • GlobeNewswire

    Celularity Appoints Industry Leader Diane Parks to its Board of Directors

    Pharmaceutical and Biotech Industry Veteran Brings Significant Strategic Development and Commercialization Expertise Launching New Cellular TherapiesFLORHAM PARK, N.J., June 03, 2022 (GLOBE NEWSWIRE) -- Celularity Inc. (Nasdaq: CELU) (“Celularity”), a clinical-stage biotechnology company developing placental-derived off-the-shelf allogeneic cell therapies, today announced the appointment of Diane Parks to its Board of Directors. Ms. Parks, an executive with deep experience in the commercializati

  • GlobeNewswire

    Kura Oncology to Participate in Three Upcoming Investor Conferences

    SAN DIEGO, May 26, 2022 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (Nasdaq: KURA), a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicines for the treatment of cancer, today announced that Troy Wilson, Ph.D., J.D., President and Chief Executive Officer, is scheduled to participate in three upcoming investor conferences: A virtual fireside chat at Cowen’s 3rd Annual Oncology Innovation Summit at 3:30 p.m. ET / 12:30 p.m. PT on June 2, 2022; A fireside cha